2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11162
    FGF7p 2758194-43-1
    FGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of FGFR2 in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p has the advantages of low cost, good stability, and high purity. FGF7p is commonly used in the study of inflammatory conditions.
    FGF7p
  • HY-P11179
    VTEHDTLLY 481651-50-7 98%
    VTEHDTLLY is a HLA class I-restricted CMV peptide epitope. VTEHDTLLY can be used in the research of CMV-specific T cell expansion.
    VTEHDTLLY
  • HY-P1117A
    MMK1 TFA 98%
    MMK1 TFA is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC50s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 TFA is a potent chemotactic and calcium-mobilizing agonist. MMK1 TFA potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 TFA exerts anxiolytic-like activity.
    MMK1 TFA
  • HY-P11181
    Chorionic Gonadotropin-beta (109-145) (human)
    Chorionic Gonadotropin-beta (109-145) (human) is the carboxyl-terminal part (109-145) of the human chorionic gonadotropin beta subunit. Chorionic Gonadotropin-beta (109-145) (human) can be used in the research of immune responses.
    Chorionic Gonadotropin-beta (109-145) (human)
  • HY-P11183
    Cathelicidin-PY 1431866-92-0
    Cathelicidin-PY is an antimicrobial peptide exhibiting strong antimicrobial property. Cathelicidin-PY inhibits the activation of TLR4 inflammatory response pathways induced by lipopolysaccharide (LPS) (HY-D1056). Cathelicidin-PY possesses strong antimicrobial and anti-inflammatory activities and low cytotoxic ability against RAW 264.7 cells. Cathelicidin-PY can be used for antimicrobial and anti-inflammatory research.
    Cathelicidin-PY
  • HY-P1118A
    Ac9-25 TFA 98%
    Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.
    Ac9-25 TFA
  • HY-P11205
    Cys-PKHB1 2378833-51-1 98%
    Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
    Cys-PKHB1
  • HY-P11206
    Murine cardiac troponin I peptide 98%
    Murine cardiac troponin I peptide (Murine cardiac TnI peptide) is a murine cardiac troponin I (cTnI) peptide. Murine cardiac troponin I peptide can induce significant myocardial inflammation followed by fibrosis and heart failure with increased mortality in mice model. Murine cardiac troponin I peptide can be used for heart failure research.
    Murine cardiac troponin I peptide
  • HY-P11207
    NLS-CPP 1228086-59-6
    NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA).
    NLS-CPP
  • HY-P11208
    mNLS-CPP-WSTF
    mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
    mNLS-CPP-WSTF
  • HY-P11210
    A68828 132309-52-5
    A68828 is an atrial natriuretic factor (ANF) analog. A68828 can improve renal function in an acute model of postischemic acute renal failure. A68828 can be studied in research on ischemic acute renal failure.
    A68828
  • HY-P11214
    Hydrostatin-TL1 2243975-43-9
    Hydrostatin-TL1 (H-TL1), a nine-amino-acid peptide, is a TNF-α antagonist. Hydrostatin-TL1 can be isolated from the venom gland of sea snake Hydrophis cyanocinctus. H-TL1 competitively inhibits the interaction between TNF-α/TNFR1 and attenuates the cytotoxicity and inflammation of TNF-α. Hydrostatin-TL1 can be used for TNF-α-associated inflammatory diseases, such as rheumatoid arthritis, osteoporosis and inflammatory bowel disease (IBD) research.
    Hydrostatin-TL1
  • HY-P11223
    CMF9 98%
    CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers α-SMA and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis.
    CMF9
  • HY-P11229
    GGGGSGGGGS 192805-56-4
    GGGGSGGGGS is a chimeric peptide composed of four peptides. GGGGSGGGGS can efficiently bind to small intestinal submucosa (SIS) membranes. GGGGSGGGGS can be used for research on infectious or inflammatory conditions.
    GGGGSGGGGS
  • HY-P11230
    Dpep24
    Dpep24 is a highly selective and affinity cyclic D-type sulfated peptide inhibitor. Dpep24 can target and inhibit the inflammatory chemokine CCL22 (KD = 190 nM). Dpep24 can be used for research on inflammatory conditions.
    Dpep24
  • HY-P11241
    oNCM
    oNCM is an antibacterial peptide. oNCM has good antibacterial activity, anti biofilm ability, anti-inflammatory effect, high stability, and low cytotoxicity. oNCM can be used for research on infectious or inflammatory conditions.
    oNCM
  • HY-P11250
    HVF18-a3-d
    HVF18-a3-d is an antimicrobial peptide. HVF18-a3-d reduces NO production. HVF18-a3-d inhibits the production of TNF-α and IL-6, reduces ROS production, and suppresses the TLR4 signaling pathway, as well as LPS-induced phosphorylation of ERK, JNK, and p38 MAPK. HVF18-a3-d exhibits antimicrobial activity against a variety of bacteria by disrupting their outer and inner membranes. HVF18-a3-d protects mice from fatal septic shock induced by Acinetobacter baumannii resistant to Carbapenem. HVF18-a3-d shows anti-inflammatory and antioxidant effects.
    HVF18-a3-d
  • HY-P11253
    DOTA-Bn-CA-170
    DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
    DOTA-Bn-CA-170
  • HY-P11258
    UPG-108 3090686-88-4
    UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system.
    UPG-108
  • HY-P11259
    UPG-111 3090687-02-5
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system.
    UPG-111
Cat. No. Product Name / Synonyms Application Reactivity